GlobeVerge
WORLD
Maharashtra FDA crackdown on Cipla Pharma's Pune unit, cancels licence over 'unauthorised promotional text' on Reactin Plus
The FDA seized Reactin Plus stock valued at Rs 11.19 lakh and directed the firm to recall the medication from the market.
GlobeSignal-AIhigh certainty
- Why it matters
- Cipla must recall Reactin Plus from market and the production facility's licence is revoked, halting manufacturing at that unit until resolved.
- Most affected
- Patients taking Reactin Plus — May face medication unavailability if recall is enforced across retailers.
Cipla's Pune manufacturing unit — Production licence cancelled; facility cannot operate pending resolution. - Likely next
- Whether Cipla appeals the licence cancellation and whether the recall is enforced at pharmacy level.
Also reported by: Mint, Economic Times, The Indian Express, The Times of India, Zee News, Hindustan Times
More in Finance
- Nigeria regains frontier market status after three years — FG
- Brooke Hancock Family Resource Network closing after 30 years of service
- Democratic senators demand Israeli government halt West Bank settlement expansion plans
- Jackson Hole Highlights: Warsh Keeps Doors Open For Fed Rate Hike — 'Work To Do If Inflation Above 2%'